With an increase in sales of 230% in 2003 Scienion has impressively shown the market acceptance of innovative products and services
In the dynamic and competitive market of biochip technology the Berlin-based company has become a successful and well recognised player.
CEO Holger Eickhoff attributes this achievement to Scienion's business model: "We market a solid technology accompanied by a platform wide service, therefore helping to solve problems effectively.
"Our customer oriented approach and the high quality of products and services are reflected in the increasing revenues and in increasing numbers of customers".
One of the highlights in 2003 was the set up of the business unit hardware, especially the successful launch of a modular dispensing system for ultra low level liquid handling.
The Sciflexarrayer transports samples - DNA, proteins or cells - with precisely defined volumes at defined locations onto carriers.
In May 2003 Scienion started the project 'Obesity-Chip' together with partners of the Charite and the Fraunhofer Institute for Biomedical Engineering.
The intention of the joint project is the chip-based identification and analysis of the genetically based factors of obesity in order to enable a better diagnosis and eventually a therapy.
As part of the BioProfile emphasis of the Nutrigenome Research Berlin-Brandenburg the project is funded by the German Ministry of Education and Research.
2004 already started with good news: Scienion and Greiner BioOne have developed new formats for microarrays and offer combined solutions.
With the joint launch of these HTA platforms (high-throughput micro arraying) and the adaptation of the Sciflexarrayer for loading these new carriers, Scienion offers new cost-effective solutions for the use of microarray technologies in the diagnostic market.
